NCT06458712
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Recruiting · Phase 1 · Duke Street Bio Ltd · registry updated 2026-09-02
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
Inclusion
- The participant (or legally acceptable representative, if applicable) provides written informed consent for the study.
- Aged ≥18 years of age on the day of signing the informed consent.
- Histologically confirmed diagnosis of locally advanced and/or metastatic breast cancer, prostate cancer (mCRPC), ovarian cancer, or pancreatic ductal adenocarcinoma (PDAC) with confirmed gene alterations/ mutations as defined in the protocol
- Has received prior cancer treatment as outlined in the protocol
- Has measurable disease per RECIST v1.1, or non-measurable disease as defined in the protocol.
- ECOG performance status of 0 to 1.
Exclusion
- Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or features suggestive of MDS/AML.
- Has received a prior PARP1-selective inhibitor.
- Has received prior systemic anti-cancer therapy including investigational agents or device within 2 or 4 weeks prior to study intervention, dependent on the treatment.
- Received prior radiotherapy within 2 weeks of the start of study intervention or has a history of radiation pneumonitis.
- Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: administration of killed vaccines are allowed.